15 results about "Latent tuberculosis" patented technology

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

This invention discloses miRNA biomarkers for the auxiliary diagnosis of tuberculosis and their applications. This invention claims protection for the use of substances for detecting miRNAs in serum exosomes in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of tuberculosis patients or for the diagnosis or auxiliary diagnosis of active pulmonary tuberculosis patients. The miRNAs are any one or any combination of the following five miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246, and miR-2110. This invention also claims protection for the use of substances for detecting serum exosome miRNAs in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of latent tuberculosis infection. The miRNAs are any one or any combination of the following three miRNAs: let-7e-5p, let-7d-5p, and miR-140-5p. This invention lays the foundation for further development of rapid early diagnosis techniques and methods for tuberculosis.

The invention belongs to the technical field of tuberculosis detection, and provides a microRNA combination for bimodal differentiation of tuberculosis infection, a kit and a detection system. Nine specific microRNAs and one specific internal reference microRNA are taken as markers, the microRNAs in plasma are rapidly released by adopting a direct splitting method, the relative expression quantity of the markers is synchronously detected in combination with a tailing method reverse transcription technology, a four-group primer grouping amplification technology and a fluorescent PCR technology, a comprehensive risk value is calculated through a built-in algorithm, and latent tuberculosis infection, active infection and a negative state are synchronously distinguished. According to the invention, sputum samples are not needed, the detection is rapid and efficient, the detection sensitivity and specificity of active tuberculosis infection reach 92%, the detection sensitivity and specificity of latent tuberculosis infection reach 93%, the detection specificity reaches 90%, the operation is convenient, and the application range is wide.

The application discloses a gene marker for diagnosing latent tuberculosis infection and application thereof, and belongs to the technical field of biological medicine. The application screens a latent tuberculosis infection early diagnosis marker based on peripheral blood whole genome DNA methylation map, provides a new target for diagnosing latent tuberculosis infection, evaluates the diagnosis efficiency of the marker through pyrosequencing, develops a corresponding detection kit and a use method, and realizes rapid and accurate diagnosis of latent tuberculosis infection.

The disclosure concerns a method of obtaining information about the disease status of an individual by processing input data using a trained machine learning algorithm model to generate an output representing the information. The disclosure also concerns a related computer program, data processing apparatus, and system, as well as a method for training a machine learning algorithm model to generate information about the disease status of an individual. The information may, for example, relate to the presence, absence or type of M. tuberculosis complex infection in the individual.

The application discloses an activity / inactivity tuberculosis recognition system based on an improved 3D network, which comprises an image feature acquisition module, a data preprocessing module, an image segmentation module and an image classification recognition module. The image feature acquisition module is used for acquiring lung tuberculosis CT chest image features. The data preprocessing module is used for performing data preprocessing on the acquired lung tuberculosis CT chest image features. The image segmentation module is used for segmenting the preprocessed lung tuberculosis CT chest image features to acquire lung parenchyma image features, and a segmentation model adopted is a 3D ResUNet segmentation model. The image classification recognition module is used for performing prediction classification on the lung parenchyma image features after image segmentation. An image classification model adopted is a 3D ResUNet50 classification model, and the 3D ResUNet50 classification model is combined with a multi-scale attention module to obtain image output features. Then, grouping convolution and channel shuffling are used to process the image output features, the categories of active and inactive tuberculosis are predicted, and the confidence score of the model is generated. The application can improve the CT image classification accuracy of the model.

The present disclosure provides a use of a fusion protein EH containing a tuberculous allergen or a pharmaceutical composition containing the fusion protein EH in the preparation of a reagent or kit for immunological diagnosis of tuberculosis, auxiliary diagnosis of tuberculosis or screening of latent tuberculosis infection of Mycobacterium tuberculosis, the fusion protein EH containing ESAT6 and HspX. The recombinant allergen EH provided by the present disclosure has good specificity and high sensitivity, can be suitable for large-scale screening, and is a new generation of LTBI screening and diagnosis product technology with application and development potential. The recombinant allergen EH provided by the present disclosure has lower toxicity compared with EC, and is safer.

The application discloses a fusion protein PP13138R and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, PorB, PADRE and RS-09. The application screens 34 epitopes for Mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and no sensitization, and have the characteristics of high population coverage and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and the PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The PP13138R has the advantages of simple preparation method, low cost, high yield and higher safety as a vaccine. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The invention relates to a novel coding gene Rv3864c (-4341113-4341511) of mycobacterium tuberculosis H37Rv and a coding protein of the novel coding gene Rv3864c (-4341113-4341511). The Rv3864c gene has high specificity, secretory property and antigenicity, and can be independently or jointly used for clinical rapid screening of latent tuberculosis infected persons and active tuberculosis patients and protecting human bodies from being infected by mycobacterium tuberculosis.

The application can diagnose the infection of a tuberculosis patient by detecting the expression amount of the LLGL2 gene, and the detection method is simple, fast, and has high detection quality and accuracy, and the sensitivity and specificity are all greater than 80%. When the expression amount of the biomarker LLGL2 gene is greater than 1.476, the subject is judged as a latent tuberculosis infection patient; when the expression amount of the biomarker LLGL2 gene is less than or equal to 1.476, the subject is judged as not suspected to be a latent tuberculosis infection patient, and needs further diagnosis. When the expression amount of the biomarker LLGL2 gene is less than 0.8653, the subject is judged as an active tuberculosis patient; when the expression amount of the biomarker LLGL2 gene is greater than or equal to 0.8653, the subject is judged as not suspected to be an active tuberculosis patient, and needs further diagnosis.

The invention discloses a method for detecting latent infection of tubercle bacillus, and belongs to the field of tuberculosis detection. According to the method, detection of latent infection of tubercle bacillus is completed through the steps of sample collection, sample treatment, marker detection, data analysis, result judgment and the like. According to the invention, mycobacterium tuberculosis specific extracellular RNA (exoRNA) is selected as a novel biomarker. Compared with the traditional protein or DNA marker, the exoRNA has higher sensitivity and specificity, and can reflect the existence and activity state of the pathogen earlier and more accurately. The application of the marker effectively reduces the risk of cross reaction caused by bacillus calmette guerin vaccine inoculation or nontuberculous mycobacterium infection, thereby improving the reliability of the detection result. According to the invention, a high-throughput sequencing technology and an artificial intelligence algorithm are combined, and an intelligent diagnosis model is constructed. The method not only can realize qualitative judgment of LTBI, but also can finely distinguish infection states by analyzing the combination and expression profile of the exoRNA markers.

The application discloses a fusion protein HP13138PB and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, HBD-3, PSM alpha 4 and PADRE. The application screens 34 epitopes for mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and sensitization, and have the characteristics of high population coverage and the like. The immunogenicity of the vaccine is improved by further adding antibacterial peptide HBD-3 and auxiliary peptide PADRE, and PSM alpha 4 is added to endow the vaccine with targeted delivery function. In-vitro experiments prove that HP13138PB can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The HP13138PB as a vaccine has the advantages of simple preparation method, low cost, high yield and higher safety and the like. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

This invention discloses the polypeptide fusion protein CP13138P and its application in tuberculosis prevention. Specifically, it discloses a fusion protein comprising tandem HTL, CTL, and B-cell epitopes, CTB, Pam2Cys, and PADRE. This invention screened 34 epitopes targeting Mycobacterium tuberculosis, which exhibit excellent immunogenicity and antigenicity, are non-toxic and non-sensitizing, and have high population coverage. In vitro experiments demonstrate that CP13138P can stimulate an immune response in human peripheral blood mononuclear cells (PBMCs), increasing IFN-γ in PBMCs. + The number of T lymphocytes is significantly increased, and they secrete significantly high levels of more than a dozen cytokines, including G-CSF, making them a dominant protective antigen. CP13138P, as a vaccine, has advantages such as simple preparation method, low cost, high yield, and enhanced safety. This invention has significant value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

This invention discloses the fusion protein PP19128R and its application in the prevention or treatment of Mycobacterium tuberculosis infection. Specifically, it discloses a fusion protein comprising tandem HTL, CTL, and B-cell epitopes, PorB, RS-09, and PADRE. This invention screened 39 epitopes targeting Mycobacterium tuberculosis, which exhibit excellent immunogenicity and antigenicity, are non-toxic and non-sensitizing, and have high population coverage. The helper peptide PADRE is further added to enhance the immunogenicity of the vaccine, and PorB and RS-09 are added to endow the vaccine with targeted delivery function. In vitro experiments demonstrate that PP19128R can stimulate an immune response in human peripheral blood mononuclear cells, making it a superior protective antigen. PP19128R as a vaccine has advantages such as simple preparation method, low cost, high yield, and enhanced safety. This invention has significant value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The present invention relates to a composition and imaging technology for evaluating the immune response of T cells, and in particular, to the technological field of T cell activation analysis and infectious disease diagnosis using lens-free shadow imaging. According to the present invention, activation of T cells can be effectively induced through a T cell activation composition composed of a specific component combination (PHA, PMA, ionomycin, etc.), and T cell activation-specific image parameters (MMD_SD etc.) can be acquired from the activated T cells through lens-free shadow imaging technology. Moreover, since a T cell activity analysis device and method using these parameters exhibit significant performance in diagnosing the presence or absence of latent tuberculosis infection, the present invention has the effect of providing a biological composition that can be used for T cell functional analysis, creating a non-labeling immunodiagnostic platform, and presenting a novel analytical index for LTBI diagnosis.